Table 4. Predictive factors of new CVEs onset.
| CVEs_ month 12 | OR | SE | P | CI 95% |
|---|---|---|---|---|
| Gender | 0.80 | 0.84 | 0.84 | 0.10–6.37 |
| Age#familiarity_No | 1.16 | 0.05 | 0.001* | 1.06–1.27 |
| Age#familiarity_Yes | 1.18 | 0.05 | 0.001* | 1.07–1.29 |
| Smoke | 0.99 | 0.77 | 0.99 | 0.21–4.60 |
| BMI | 1.42 | 0.71 | 0.48 | 0.53–3.79 |
| Cholesterol_month 12 | 1.00 | 0.03 | 0.67 | 0.98–1.01 |
| Triglycerides_month 12 | 1.01 | 0.00 | 0.02* | 1.00–1.02 |
| Glycemia_month 12 | 0.98 | 0.01 | 0.33 | 0.95–1.01 |
| MS | 0.43 | 0.36 | 0.319 | 0.08–2.24 |
| T2D | 0.36 | 0.30 | 0.22 | 0.07–1.85 |
| SAH | 12.63 | 16.39 | 0.04* | 0.99–160.62 |
| Disease duration | 0.99 | 0.45 | 0.92 | 0.91–1.08 |
| No EULAR response_month 12 | 8.26 | 7.52 | 0.02* | 1.38–49.20 |
| Moderate EULAR response_month 12 | 5.34 | 4.13 | 0.03* | 1.17–24.32 |
| Good response_month 12 | 1 |
Abbreviations: CVEs cerebro-cardiovascular events; BMI: body mass index; SAH: Systemic Arterial Hypertension; MS: Metabolic syndrome; T2D: Type 2 diabetes.
*:statistically significant